Published in J Immunol on October 01, 1974
Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells. Proc Natl Acad Sci U S A (1976) 1.88
Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice. Proc Natl Acad Sci U S A (1977) 1.49
In vitro production and cellular origin of murine type II interferon. Immunology (1979) 1.39
Inhibition by interferon of delayed-type hypersensitivity in the mouse. Proc Natl Acad Sci U S A (1975) 1.34
Detection of gamma interferon in the sera of patients with Behçet's disease. Infect Immun (1982) 1.33
Electrophoretically pure mouse interferon exerts multiple biologic effects. Proc Natl Acad Sci U S A (1979) 1.28
Induction of interferon in ovine and human lymphocyte cultures by mycoplasmas. Infect Immun (1976) 1.24
Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med (1983) 1.18
Interferon preparations enhance phagocytosis in vivo. Infect Immun (1976) 1.06
Immunosuppressive effects of lymphocyte (type II) and leucocyte (type I) interferon on primary antibody responses in vivo and in vitro. Clin Exp Immunol (1977) 0.93
Interferon inhibition of lymphocyte mitogenesis. Immunology (1977) 0.90
Complement-dependent, polymorphonuclear neutrophil-mediated cytotoxicity of herpesvirus-infected cells: possible mechanism(s) of cytotoxicity. Immunology (1980) 0.90
Characterization of a soluble suppressor of human B cell immunoglobulin biosynthesis produced by a continuous human suppressor T cell line. J Exp Med (1981) 0.87
Proliferative and functional aspects of interferon-treated human normal and neoplastic T and B cells. Br J Cancer (1980) 0.83
Interferon induction by the immunomodulating polyanion lambda carrageenan. Infect Immun (1979) 0.77
Immunoglobulin production by peripheral blood mononuclear cells in patients with alcoholic liver disease. Clin Exp Immunol (1984) 0.77
Protective effect of low-dose interferon against neonatal murine cytomegalovirus infection. Infect Immun (1981) 0.76
Interferon induction by adenoviruses. Postgrad Med J (1979) 0.75
Immunoregulatory effects of cloned T cells on B-cell responses: comparison of autoimmune and non-autoimmune derived clones. Immunology (1989) 0.75
Immune reactivity of Visna virus-inoculated mice. Infect Immun (1978) 0.75
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol (1983) 4.09
Global genetic structure and molecular epidemiology of encapsulated Haemophilus influenzae. Rev Infect Dis (1990) 4.06
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. N Engl J Med (1983) 3.83
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science (1968) 3.65
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med (1998) 3.55
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med (1996) 3.35
Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol (1991) 3.32
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Concerning the mechanism of action of interferon. Proc Natl Acad Sci U S A (1966) 3.15
Inhibition of respiratory virus infection by locally applied interferon. Lancet (1973) 3.02
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol (1999) 2.89
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest (1998) 2.88
On-line computer quality control of antibiotic-sensitivity testing. N Engl J Med (1970) 2.88
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis (1991) 2.86
Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med (1976) 2.80
Inhibition of TRIC agents by virus-induced interferon. Proc Soc Exp Biol Med (1966) 2.78
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
Physical properties of human interferon prepared in vitro and in vivo. Virology (1966) 2.62
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol (2001) 2.45
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med (1999) 2.36
Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc Natl Acad Sci U S A (1984) 2.32
Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus. J Infect Dis (1982) 2.29
Evolution of recurrent herpes simplex lesions. An immunohistologic study. J Clin Invest (1985) 2.28
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis (1993) 2.28
Interferon inducers in vitro: difference in sensitivity to inhbitiros of RNA and protein synthesis. Science (1968) 2.16
Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology (1988) 2.14
Cellular immunity and herpesvirus infections in cardiac-transplant patients. N Engl J Med (1977) 2.09
Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons. J Immunol (1975) 2.09
Measles in adults. An unforeseen consequence of immunization? JAMA (1976) 2.08
Patient compliance and drug failure in protease inhibitor monotherapy. JAMA (1996) 2.06
Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med (1978) 2.04
Interferon-stimulating and in vivo antiviral effects of various synthetic anionic polymers. Virology (1968) 1.96
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol (1993) 1.94
Synthetic polyanions protect mice against intracellular bacterial infection. Nature (1970) 1.92
Induction of circulating interferon by synthetic anionic polymers of known composition. Nature (1967) 1.92
Interferon and cytomegalovirus in vivo and in vitro. Proc Soc Exp Biol Med (1967) 1.85
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest (1991) 1.85
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis (1995) 1.79
Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis (1995) 1.77
Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med (1997) 1.76
The interaction of human macrophages and lymphocytes in the phytohemagglutinin-stimulated production of interferon. J Clin Invest (1971) 1.75
PPD-stimulated interferon: in vitro macrophage-lymphocyte interaction in the production of a mediator of cellular immunity. Cell Immunol (1971) 1.75
Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. J Clin Microbiol (1997) 1.74
Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med (1973) 1.73
A useful quantitative semimicromethod for viral plaque assay. Proc Soc Exp Biol Med (1973) 1.73
Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination. Proc Natl Acad Sci U S A (1972) 1.73
Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. J Virol (1985) 1.73
Viral infections in man associated with acquired immunological deficiency states. Fed Proc (1972) 1.70
Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes. J Clin Microbiol (1995) 1.69
An artificial intelligence program to advise physicians regarding antimicrobial therapy. Comput Biomed Res (1973) 1.69
Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS (1999) 1.68
Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus. Infect Immun (1976) 1.67
Interferon, antibody, and other host factors in herpes zoster. J Clin Invest (1972) 1.64
The immunosuppressive effect of type II mouse interferon preparations on antibody production. Cell Immunol (1977) 1.64
Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody. Infect Immun (1985) 1.60
Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol (1984) 1.60
Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med (1984) 1.58
Bis-DEAE-fluorenone: mechanism of antiviral protection and stimulation of interferon production in the mouse. J Infect Dis (1971) 1.56
Herpes Zoster-Varicella infections and lymphoma. Ann Intern Med (1972) 1.54
Current concepts of interferon and interferon induction. Annu Rev Med (1970) 1.53
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation (1999) 1.52
Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. J Infect Dis (1978) 1.51
Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology (1981) 1.49
The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86. Virology (1989) 1.49
Immune specific production of interferon by human T cells in combined macrophage-lymphocyte cultures in response to Herpes simplex antigen. J Immunol (1975) 1.49
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol (1997) 1.48
Parameters affecting ascites tumour formation in mice and monoclonal antibody production. J Immunol Methods (1984) 1.48
Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J Virol (1995) 1.48
Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest (1980) 1.48
Hereditary occurrence of cystic disease of the renal medulla. N Engl J Med (1966) 1.46
HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr (1994) 1.44
Diagnosis of cytomegalovirus pneumonia in compromised hosts. Am J Med (1976) 1.44
Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med (1978) 1.44
Time and dosage dependence of immunoenhancement by murine type II interferon preparations. Cell Immunol (1978) 1.43
Requirement of a stable secondary structure for the antiviral activity of polynucleotides. Nature (1969) 1.43
Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis (1991) 1.43
Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med (1978) 1.42
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother (1997) 1.42
Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA (1982) 1.42
Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease. Arthritis Rheum (1981) 1.41
Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses. J Infect Dis (1974) 1.40
Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis (1978) 1.40
Resistance to virus challenge in mice infected with protozoa or bacteria. Proc Soc Exp Biol Med (1969) 1.40
Cytomegalovirus retinitis in immunosuppressed hosts. II. Ocular manifestations. Ann Intern Med (1980) 1.39
Toxicity of vidarabine. JAMA (1979) 1.39
In vitro production and cellular origin of murine type II interferon. Immunology (1979) 1.39
Antiproliferative effects of recombinant alpha- and gamma-interferons on cultured human keratinocytes. Lab Invest (1984) 1.38
Septicemia with Pasteurella pseudotuberculosis and liver disease. Arch Intern Med (1971) 1.37
Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J Infect Dis (1981) 1.36
Role of T lymphocytes in cellular immune responses during herpes simplex virus infection in humans. Proc Natl Acad Sci U S A (1978) 1.35
Cutaneous interferon production in patients with Hodgkin's disease and other cancers infected with varicella or vaccinia. N Engl J Med (1970) 1.34
Identification of cell surface receptors for the 86-kilodalton glycoprotein of human cytomegalovirus. Proc Natl Acad Sci U S A (1989) 1.34
Effect of vidarabine on chronic hepatitis B virus infection. JAMA (1978) 1.34